Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
Frontiers in Medicine|May 30, 2024
A randomized, double-blinded, phase 2 trial of EDP1815, an oral immunomodulatory preparation of Prevotella histicola, in adults with mild-to-moderate plaque psoriasisBenjamin D Ehst, Bruce Strober, Andrew Blauvelt, et al.American Journal of Clinical Dermatology|September 27, 2025
Summary of Research: Efficacy and Safety of Delgocitinib Cream in Adults with Moderate to Severe Chronic Hand Eczema (DELTA 1 and DELTA 2): Results from Multicentre, Randomised, Controlled, Double-Blind, Phase 3 TrialsRobert Bissonnette, Fatima Albreiki, Benjamin D Ehst, et al.Rheumatology (Oxford, England)|November 1, 2013
Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapyCara D Varley, Atul A Deodhar, Benjamin D Ehst, et al.Immunity|July 23, 2003
Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunityAndrea A Itano, Stephen J McSorley, R Lee Reinhardt, et al.Journal of Immunology (Baltimore, Md. : 1950)|March 9, 2004
Indirect minor histocompatibility antigen presentation by allograft recipient cells in the draining lymph node leads to the activation and clonal expansion of CD4+ T cells that cause obliterative airways diseaseDavid M Richards, Stacy L Dalheimer, Benjamin D Ehst, et al.Dermatology and Therapy|April 5, 2025
Health-Related Quality of Life in Chronic Hand Eczema in a Phase 2b Trial of Delgocitinib CreamTimo Buhl, Andrea Bauer, Benjamin D Ehst, et al.Nature|March 4, 2005
CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell deathEdith M Janssen, Nathalie M Droin, Edward E Lemmens, et al.The Journal of Dermatological Treatment|January 12, 2025
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trialsLinda Stein Gold, James Del Rosso, Benjamin D Ehst, et al.Nature Communications|December 11, 2025
A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumabAndrew Blauvelt, Rundong Jiang, Linyu Shi, et al.American Journal of Clinical Dermatology|February 8, 2026
Expert Recommendations for the Diagnosis and Management of Chronic Hand Eczema in the United StatesJonathan I Silverberg, David Cohen, Emma Guttman-Yassky, et al.Pageof 3